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 Letters to Dermatology 
present a case after 1 treatment course of 12 weeks with alefacept 
resulting in long duration of remission as a meaningful measure in 
psoriasis management. 
 Case Report 
 A 64-year-old female overweight Caucasian with a positive fam-
ily history for psoriasis had been suffering from chronic plaque-type 
psoriasis since 1995. Several conventional treatment modalities 
including UVB at 311 nm were applied, but induced generally only 
short remissions. In May 2003, she presented with moderate plaque 
psoriasis involving the trunk, lower extremities and elbows as well 
as nail stippling and thick hyperkeratotic scalp lesions. The body 
surface area (BSA) was about 20%, the physician global assessment 
(PGA) was moderate to severe and the psoriasis area severity index 
(PASI) amounted to 18. Using the visual analogue scale (VAS) from 
number 0 to 10, the patient herself estimated to have a disease ac-
tivity of 9  indicating severe psoriasis. Because quality of life was 
indeed markedly decreased and feelings of the patient were frustrat-
ing, a therapy with alefacept was initiated. According to the treat-
ment recommendation, alefacept was applied at a dose of 15 mg 
weekly intramuscularly for 12 weeks. Topical treatment with calci-
potriene twice daily was continued during alefacept therapy for a 
total of 6 weeks; after that, only the use of emollients was indicated. 
At the subsequent weekly visits, physical examination, PASI, BSA, 
VAS, PGA and laboratory fi ndings, especially CD4+ lymphocyte 
counts, were assessed. During the 12 weeks of active treatment, a 
slowly but incremental improvement of skin condition was 
achieved, resulting in a BSA of 8% and a PASI of 5.9  after 7 weeks 
of treatment. Finally, after 12 weeks, a remarkable improvement 
resulted in a BSA of 2% and a PASI of 1.0  ( fi g. 1 ). The plaques dis-
appeared leaving only mild erythema. At this time, the patient as-
sessed her disease using the VAS as 0. No application site reactions, 
relevant changing of lymphocyte count or any other adverse events 
were observed. After the active treatment period of 3 months, a 
follow-up period was accomplished. In this postdosing phase, the 
psoriasis cleared within 2 weeks. There was therefore no longer any 
necessity for any topical therapy. After a 12-week follow-up, the 
next subsequent 12-week treatment course was planned but not 
initiated due to the patient’s good skin condition. One year after 
the end of the active treatment course of alefacept, the skin is still 
almost clear (BSA: 3%, PASI: 2.0, PGA  almost clear, VAS: 0). In 
the entire postdosing period, no unwanted side effects were noted. 
A further follow-up will be done. 
 Discussion 
 For the treatment of psoriasis there are new biologic agents like 
alefacept, efalizumab and TNF-  antagonists available. Here, we 
take advantage of our long-lasting experience with alefacept in the 
therapy of psoriasis. Like other protein-based biologic agents, ale-
facept has to be applied generally by the parenteral route (e.g. 7.5 
mg intravenously or 15 mg intramuscularly over 12 weeks followed 
by a 12-week follow-up). The large pivotal clinical trials reveal 
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 Introduction 
 Alefacept is a recombinant human leukocyte function antigen 
(LFA) 3/immunoglobulin G1 fusion protein that is being designed 
to prevent the interaction between LFA-3 and CD2  [1] . Addition-
ally, the protein is able to induce apoptosis in critical subgroups of 
T cells (CD45RO+ memory T cells) by engaging Fc  RI and
Fc  RIII immunoglobulin receptors  [2] . Alefacept has been ap-
proved by the FDA for treatment of moderate to severe chronic 
plaque psoriasis in the USA and very recently also in Israel and 
Switzerland. Due to its dual mechanism of action that results in 
inhibition of T cell activation and selective reduction of memory 
T cells, the CD4+ cell count has to be regularly monitored, i.e. 
weekly. Because of the long experience with alefacept by both clin-
ical trials and medical use far from studies, excepting T cell counts 
no important changes in laboratory values, vital signs and physical 
examinations were observed  [2] . Therefore, alefacept seems to be 
ideally suited for the long-term treatment of psoriasis. Here, we will 
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overall response rates after 1 intravenous dosing course of 12 weeks 
of 56% ( 6 PASI 50) and of 28% ( 6 PASI 75) that increase in the 
second course to 71% ( 6 PASI 50) and 40% ( 6 PASI 75), respec-
tively. The corresponding PASI score of a placebo group dropped 
behind to 24% ( 6 PASI 50) and 8% ( 6 PASI 75)  [3] . Similar results 
could be consistently achieved by the phase III study of 15 mg i.m. 
once weekly  [4, 5] . As a matter of experience, alefacept is to be 
considered as a slowly acting biologic agent with incremental ef-
fectiveness of 2 or more treatment cycles. However, the fusion 
protein is characterized essentially by a good tolerability and its 
safety. The adverse event profi le demonstrated by clinical studies 
reveals no statistically signifi cant differences to placebo. Alefa-
cept’s mechanism of action, management of treatment and adverse 
reaction profi le are well documented. Very recently, additional 
fi rst evidence could be provided that a reduced biweekly monitor-
ing schedule for CD4+ T cells is not associated with an increased 
risk from alefacept treatment. Although combination therapy was 
not the primary reason for developing alefacept, preliminary data 
suggest that the immune modulator might be safely administered 
in combination with other conventional psoriasis therapies aiming 
 Fig. 1. PASI (score points), BSA (%), PGA (score points) and CD4+ 
cells (cells/l) before, during and after alefacept therapy. 
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at a further improvement like cyclosporine, systemic retinoids and 
others. 
 Much interest has been focused on the determination of the re-
sponse duration of alefacept therapy after stopping therapy  [2, 3, 
5, 6] . These data have clearly demonstrated a statistically median 
duration of approximately 6–7 months if defi ned as the time that 
patients maintained a  6 50% reduction from baseline PASI for 
those patients who achieved a  6 75% reduction from baseline PASI 
at any time during or after treatment. The rationale for the long-
lasting remission effect of alefacept is chiefl y attributed to the in-
hibition of T cell activation and proliferation as well as apoptosis 
of those T cells expressing high levels of CD2 (e.g. activated 
CD4+CD45RO+, CD8+CD45RO+ cells)  [6] . Thus, as a rule the 
response to alefacept is durable in most patients. Because in our 
patient the duration of remission indeed amounted to approxi-
mately over 1 year, this observation indicates obviously existing 
subsets of patients suffering from a chronic stable type. To obtain 
a more precise understanding of alefacept’s action in terms of dura-
tion of remission, direct examination of different responders has 
yet to be carefully made. 
 
